Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases
Phase I/II Study of Stereotactic Radiation and Sacituzumab Govitecan With Zimberelimab in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases (TARGET-TNBC)
Sponsor: Gilead Sciences
A PHASE1/PHASE2 clinical study on Breast Cancer and Triple Negative Breast Cancer, this trial is actively recruiting participants. The trial is conducted by Gilead Sciences and has accumulated 13 data snapshots since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
13 versions recorded-
Jan 2026 — Present [monthly]
Recruiting PHASE1/PHASE2
-
Oct 2025 — Jan 2026 [monthly]
Recruiting PHASE1/PHASE2
-
Jun 2025 — Oct 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Mar 2025 — Jun 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Dec 2024 — Mar 2025 [monthly]
Recruiting PHASE1/PHASE2
Status: Not Yet Recruiting → Recruiting
▶ Show 8 earlier versions
-
Nov 2024 — Dec 2024 [monthly]
Not Yet Recruiting PHASE1/PHASE2
-
Oct 2024 — Nov 2024 [monthly]
Not Yet Recruiting PHASE1/PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Not Yet Recruiting PHASE1/PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE1/PHASE2
-
Jul 2024 — Aug 2024 [monthly]
Not Yet Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Apr 2024 — Jun 2024 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Mar 2024 — Apr 2024 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Gilead Sciences
- H. Lee Moffitt Cancer Center and Research Institute
For direct contact, visit the study record on ClinicalTrials.gov .